Centessa Pharmaceuticals Reports Q1 2025 Results: Net Loss Narrows to $26.1M, R&D Expenses Increase by 47%

Reuters

2025/05/14

Centessa Pharmaceuticals Reports Q1 2025 Results: Net Loss Narrows to $26.1M, R&D Expenses Increase by 47%

Centessa Pharmaceuticals plc reported financial results for the first quarter ended March 31, 2025. The company experienced a reduction in net loss, which was $26.1 million, compared to $38.0 million for the same period in 2024. Research and Development (R&D) expenses increased to $33.4 million from $22.7 million in the previous year. Conversely, General and Administrative (G&A) expenses decreased slightly to $12.3 million from $13.4 million. The company highlighted progress in its orexin receptor 2 (OX2R) agonist pipeline, with key data readouts expected within the year. The ORX750 Phase 2a CRYSTAL-1 study is progressing for treating narcolepsy types 1 and 2, and idiopathic hypersomnia, with potential first-in-class results for NT2 and IH anticipated. Furthermore, ORX142 is set to begin first-in-human studies, and ORX489 is advancing in IND-enabling studies for neuropsychiatric disorders. These developments underscore Centessa's commitment to advancing treatments for sleep-wake disorders and related neurological conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9450919-en) on May 14, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2535223042"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535223042\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535223042?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535223042","market":"us","top_or_hot":-1,"title":"Centessa Pharmaceuticals Reports Q1 2025 Results: Net Loss Narrows to $26.1M, R&D Expenses Increase by 47%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Centessa Pharmaceuticals Reports Q1 2025 Results: Net Loss Narrows to $26.1M, R&amp;D Expenses Increase by 47%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CNTA\">Centessa Pharmaceuticals plc</a> reported financial results for the first quarter ended March 31, 2025. The company experienced a reduction in net loss, which was $26.1 million, compared to $38.0 million for the same period in 2024. Research and Development (R&amp;D) expenses increased to $33.4 million from $22.7 million in the previous year. Conversely, General and Administrative (G&amp;A) expenses decreased slightly to $12.3 million from $13.4 million. The company highlighted progress in its orexin receptor 2 (OX2R) agonist pipeline, with key data readouts expected within the year. The ORX750 Phase 2a CRYSTAL-1 study is progressing for treating narcolepsy types 1 and 2, and idiopathic hypersomnia, with potential first-in-class results for NT2 and IH anticipated. Furthermore, ORX142 is set to begin first-in-human studies, and ORX489 is advancing in IND-enabling studies for neuropsychiatric disorders. These developments underscore Centessa's commitment to advancing treatments for sleep-wake disorders and related neurological conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9450919-en) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Centessa Pharmaceuticals Reports Q1 2025 Results: Net Loss Narrows to $26.1M, R&D Expenses Increase by 47%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCentessa Pharmaceuticals Reports Q1 2025 Results: Net Loss Narrows to $26.1M, R&D Expenses Increase by 47%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-14 19:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Centessa Pharmaceuticals Reports Q1 2025 Results: Net Loss Narrows to $26.1M, R&amp;D Expenses Increase by 47%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CNTA\">Centessa Pharmaceuticals plc</a> reported financial results for the first quarter ended March 31, 2025. The company experienced a reduction in net loss, which was $26.1 million, compared to $38.0 million for the same period in 2024. Research and Development (R&amp;D) expenses increased to $33.4 million from $22.7 million in the previous year. Conversely, General and Administrative (G&amp;A) expenses decreased slightly to $12.3 million from $13.4 million. The company highlighted progress in its orexin receptor 2 (OX2R) agonist pipeline, with key data readouts expected within the year. The ORX750 Phase 2a CRYSTAL-1 study is progressing for treating narcolepsy types 1 and 2, and idiopathic hypersomnia, with potential first-in-class results for NT2 and IH anticipated. Furthermore, ORX142 is set to begin first-in-human studies, and ORX489 is advancing in IND-enabling studies for neuropsychiatric disorders. These developments underscore Centessa's commitment to advancing treatments for sleep-wake disorders and related neurological conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9450919-en) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL2NGZqb:1","article_id":"2535223042","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535223042","pubTimestamp":1747220535,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Centessa Pharmaceuticals plc reported financial results for the first quarter ended March 31, 2025. The company experienced a reduction in net loss, which was $26.1 million, compared to $38.0 million for the same period in 2024. Research and Development (R&D) expenses increased to $33.4 million from $22.7 million in the previous year. Conversely, General and Administrative (G&A) expenses decreased slightly to $12.3 million from $13.4 million. The company highlighted progress in its orexin receptor 2  agonist pipeline, with key data readouts expected within the year. The ORX750 Phase 2a CRYSTAL-1 study is progressing for treating narcolepsy types 1 and 2, and idiopathic hypersomnia, with potential first-in-class results for NT2 and IH anticipated. Furthermore, ORX142 is set to begin first-in-human studies, and ORX489 is advancing in IND-enabling studies for neuropsychiatric disorders. These developments underscore Centessa's commitment to advancing treatments for sleep-wake disorders an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","NDAQ":"纳斯达克OMX交易所","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4112":"金融交易所和数据","BK4535":"淡马锡持仓","BK4585":"ETF&股票定投概念","CNTA":"Centessa Pharmaceuticals plc","BK4539":"次新股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"Centessa Pharmaceuticals公布2025年第一季度业绩：净亏损收窄至2610万美元，研发费用增长47%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTA":0.9,"NDAQ":0.9},"content_text":"Centessa Pharmaceuticals Reports Q1 2025 Results: Net Loss Narrows to $26.1M, R&D Expenses Increase by 47%\n    \n\nCentessa Pharmaceuticals plc reported financial results for the first quarter ended March 31, 2025. The company experienced a reduction in net loss, which was $26.1 million, compared to $38.0 million for the same period in 2024. Research and Development (R&D) expenses increased to $33.4 million from $22.7 million in the previous year. Conversely, General and Administrative (G&A) expenses decreased slightly to $12.3 million from $13.4 million. The company highlighted progress in its orexin receptor 2 (OX2R) agonist pipeline, with key data readouts expected within the year. The ORX750 Phase 2a CRYSTAL-1 study is progressing for treating narcolepsy types 1 and 2, and idiopathic hypersomnia, with potential first-in-class results for NT2 and IH anticipated. Furthermore, ORX142 is set to begin first-in-human studies, and ORX489 is advancing in IND-enabling studies for neuropsychiatric disorders. These developments underscore Centessa's commitment to advancing treatments for sleep-wake disorders and related neurological conditions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9450919-en) on May 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}